الفهرس 
The use of Dehydroepiandrosterone (DHEA) in poor responders infertile patients undergoing in-vitro fertilization (IVF); A comparative study
ContentsOnly 14 pages are availabe for public view
 |  | from | 159 |  |  |
| | | from | 159 | | |
Abstract
Background: Subfertility, usually defined as absence of conception after one year of regular intercourse, is a common problem affecting as many as one in six couples. One method of treating infertile couples is assisted conception via in-vitro fertilization (IVF). Poor ovarian response (POR) is an important limiting factor to success in in-vitro fertilization (IVF) of incidence 9 to 24%. ESHRE consensus 2011 represents the first realistic attempt by the scientific community to standardize the definition of poor ovarian response (POR). Dehydroepiandrosterone (DHEA) is an endogenous adrenal steroid of several uses. DHEA is now widely used as an adjuvant to IVF treatment protocols in poor responders. It is an important endogenous steroid hormone. Aim of The Work: To investigate the efficacy and safety of DHEA versus placebo to poor responder infertile patients undergoing IVF to improve IVF outcomes and pregnancy rates. Materials and methods: Fifty poor responding infertile patients identified using ESHRE consensus, attending to the IVF center of Kasr Al-Ainy new OB-GYN hospital- Cairo university in the year 2018. All the patients were subjected to down regulation with GnRH short agonist. group A patients have received (n=25) DHEA (control group). group B patients (n=25) have received DHEA in a dose of 25 mg t.i.d. for 3 months prior to their second ICSI/embryo transfer cycle